Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

Autologous hematopoietic cell transplantation (AHCT) is a standard of care for many high-risk lymphomas, including mantle cell lymphoma [1], relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL) [2,3], T-cell NHL (T-NHL) [4], and classical Hodgkin lymphoma (HL) [5]. Unfortunately, less than half of these patients experience sustained remissions following AHCT. Patients with adverse pretransplantation risk factors, including early failure of upfront therapy [6] and persistent disease on functional imaging [7,8] have even worse outcomes.

Source: Biology of Blood and Marrow Transplantation - September 23, 2020 Category: Hematology Authors: Sherilyn A. Tuazon, Ryan D. Cassaday, Theodore A. Gooley, Brenda M. Sandmaier, Leona A. Holmberg, Stephen D. Smith, David G. Maloney, Brian G. Till, Daniel B. Martin, Victor A. Chow, Joseph G. Rajendran, Darrell R. Fisher, Manuela C. Matesan, Sally J. Lun Source Type: research